BMS reports data that could give its cell therapy an edge over rival J&J product
Bristol Myers Squibb drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in
Read more
Pharmaceuticals
Report: 3.7M people would gain coverage in 2023 if remaining states expanded Medicaid eligibility
If the 12 states that have not expanded Medicaid eligibility under the Affordable Care Act did so, 3.7 million people
Read moreAduhelm’s loss is a win for value-based drug pricing
The latest–and perhaps final–blow to the once-promising Alzheimer’s Disease medication Aduhelm came when its maker, Biogen, said it will stop
Read moreNew Versant Ventures startup goes ‘gutless’ for next-generation gene delivery
One reason engineered viruses are used to deliver genetic medicines is that viruses are very good at getting into cells.
Read moreOptimizing data mining from EHRs to improve the patient experience
In a recent webinar, Carta Healthcare CEO Matt Hollingsworth shared how his health tech business is using AI for data
Read morePenn Medicine’s venture fund makes 2 investments to address SDOH
In the past decade, large health systems such as Mayo Clinic, Kaiser Permanente and Ascension have been launching internal investment
Read moreSCAN Health Plan to move into Texas, expand presence in Nevada
SCAN Health Plan, a Medicare Advantage insurer, will begin offering health plans in two Texas counties and grow its services
Read moreAmerican Hospital Association turns up the heat on commercial insurers in scathing report
Commercial health plans use practices that delay patient care and raise administrative costs, a recent report by the American Hospital
Read moreStanford spinout raises $14M for its point-of-care physician consult service
There’s a severe evidence gap in healthcare treatment guidelines. Clinical trials shape most care guidelines and payer decisions, yet they
Read moreGetting the healthcare first impression right through smart pre-care engagement
As the saying goes, “You can’t make a second first impression.” And in no industry does a first impression carry
Read more